Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Company Overview - Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a specialty pharmaceutical company with a strong history in drug commercialization and growth [1] - The company's primary focus is on non-abusive painkillers, and it has recently expanded its portfolio to include an ADHD medication [1] Leadership and Expertise - Sunshine Kapital's Stefan, with a BA in Finance from Halmstad University and Lincolnshire & Humberside University, has twenty years of institutional experience in Research and Portfolio Management [1] - Stefan specializes in distressed situations and value opportunities and is the CIO/Founder of Sunshine Kapital, a registered investment adviser based in Miami [1]